Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NRP1 | O14786 | 2/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | ATG7 | O95352 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.31 |
| ▸ | MTAP | Q13126 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149282 | 0.84 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL10149280 | 0.82 | IMPDH2 (0.40) | ATG7 | |
| SCHEMBL866604 | 0.68 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL866385 | 0.67 | CA2 (0.49) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL26812953 | 0.66 | NRP1 (0.38) | NRP1 | |
| SCHEMBL31756654 | 0.66 | NRP1 (0.38) | NRP1 | |
| SCHEMBL865526 | 0.66 | ATG7 (0.49) | ATG7 | |
| Formycin SCHEMBL10149284 | 0.66 | HIF1A (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| Formycin SCHEMBL4196088 | 0.66 | HIF1A (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL866922 | 0.66 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | PI4KA 3835/4885PI4K2B 4393/4885PI4K2A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.